Systemic therapy for previously untreated advanced BRAF-mutated melanoma a systematic review and network meta-Analysis of randomized clinical trials

JAMA Oncology

Volumn 3, Issue 3, 2017, Pages 366-373

  Devji, Tahira ^a   Levine, Oren ^a   Neupane, Binod ^a   Beyene, Joseph ^a   Xie, Feng ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN KINASE INHIBITOR;

ANTAGONISTS AND INHIBITORS; DISEASE FREE SURVIVAL; GENETICS; HUMAN; MELANOMA; META ANALYSIS; MOLECULARLY TARGETED THERAPY; MUTATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CTLA-4 ANTIGEN; DISEASE-FREE SURVIVAL; HUMANS; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MOLECULAR TARGETED THERAPY; MUTATION; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85015350581     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.4877     Document Type: Article

References (57)

1. Lens MB, DawesM. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol. 2004;150(2): 179-185.
2. Little EG, Eide MJ. Update on the current state of melanoma incidence. Dermatol Clin. 2012;30(3): 355-361.
3. Survival statistics for melanoma. Toronto, ON: Canadian Cancer Society; 2015 [July 14, 2014]. Available from: http://www.cancer.ca/en/cancer-information/cancer-Type/skin-melanoma/prognosis-And-survival/survival-statistics/?region =on.
4. Grob JJ, Amonkar MM, Martin-Algarra S, et al. Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. Ann Oncol. 2014;25 (7):1428-1436.
5. Tsao H, Goel V, Wu H, Yang G, Haluska FG. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol. 2004;122(2):337-341.
6. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353(20):2135-2147.
7. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417 (6892):949-954.
8. ODay SJ, Hamid O, UrbaWJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): A novel strategy for the treatment of melanoma and other malignancies. Cancer. 2007;110(12):2614-2627.
9. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26): 2443-2454.
10. Wang C, Thudium KB, Han M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014;2 (9):846-856.
11. Chapman PBH, Hauschild A, Robert C, et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
12. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358-365.
13. Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867-1876.
14. Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib vs dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444-451.
15. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30-39.
16. Hodi FSOD, ODay SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. [Erratum appears in N Engl J Med. 2010 Sep 23;363(13):1290].
17. N Engl J Med. 2010;363(8):711-723.
18. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23-34.
19. PostowMA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab vs ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21): 2006-2017.
20. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab vs investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908-918.
21. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-2526.
22. Weber JS, DAngelo SP, Minor D, et al. Nivolumab vs chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375-384.
23. Larkin J, Lao CD, UrbaWJ, et al. Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-Type advanced melanoma: A pooled analysis of 4 clinical trials. JAMA Oncol. 2015;1(4):433-440.
24. Shahabi V, Whitney G, Hamid O, et al. Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab. Cancer Immunol Immunother. 2012; 61(5):733-737.
25. Jansen JP, Crawford B, Bergman G, StamW. Bayesian meta-Analysis of multiple treatment comparisons: An introduction to mixed treatment comparisons. Value Health. 2008;11(5):956-964.
26. Mills EJ, Ioannidis JP, Thorlund K, Schönemann HJ, Puhan MA, Guyatt GH. How to use an article reporting a multiple treatment comparison meta-Analysis. JAMA. 2012;308(12):1246-1253.
27. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1. 0. [updated March 2011] The Cochrane Collaboration; 2011.
28. Wilczynski NL, McKibbon KA, Haynes RB. Enhancing retrieval of best evidence for health care from bibliographic databases: calibration of the hand search of the literature. Stud Health Technol Inform. 2001;84(Pt 1):390-393.
29. NCI Common Terminology Criteria for Adverse Events (CTCAE) v.4 2010 [April 16, 2016]. http://evsnci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-8.5x11.pdf. Accessed September 21, 2016.
30. Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med ResMethodol. 2012;12:9.
31. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159-174.
32. Orwin RG. Evaluating coding decisions. In: Cooper H, Hedges LV, eds. The Handbook of Research Synthesis. New York, NY: Russell Sage Foundation; 1994:177-200.
33. Higgins J. Identifying and addressing inconsistency in network meta-Analysis: Cochrane comparing multiple interventions methods group Oxford training event. 2013. http://methods .cochrane.org/cmi/sites/methods.cochrane.org.cmi/files/uploads/S9-L%20Identifying%20and %20addressing%20inconsistency%20in %20network%20meta-Analysis.pdf. Accessed September 21, 2016.
34. Higgins JP, Thompson SG. Quantifying heterogeneity in ameta-Analysis. Stat Med. 2002; 21(11):1539-1558.
35. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-Analysis. Stat Med. 2010;29(7-8): 932-944.
36. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-Treatment meta-Analysis: An overview and tutorial. J Clin Epidemiol. 2011;64(2): 163-171.
37. Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013;31(5): 616-622.
38. Wolchok JDH, Hoos A, ODay S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-7420.
39. Ascierto PA. Is there still a role for tremelimumab in the treatment of cancer? Transl Cancer Res. 2013;2(1):48-50.
40. Gupta A, Love S, Schuh A, et al. DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-Type BRAF advanced melanoma. Ann Oncol. 2014;25(5): 968-974.
41. Hodi FSL, Lee S, McDermott DF, et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: A randomized clinical trial. JAMA. 2014;312(17): 1744-1753.
42. Kirkwood JM, Bastholt L, Robert C, et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res. 2012;18(2):555-567.
43. McArthur GAC, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323-332.
44. Robert C, Dummer R, Gutzmer R, et al. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: A phase 2 double-blind randomised study. Lancet Oncol. 2013; 14(8):733-740.
45. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320-330.
46. Robert C, Schachter J, Long GV, et al; KEYNOTE-006 investigators. Pembrolizumab vs Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521-2532.
47. Maio M, Grob JJ, Aamdal S, et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol. 2015;33 (10):1191-1196.
48. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-Type RAF to activate the MAPK pathway and enhance growth. Nature. 2010; 464(7287):431-435.
49. Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444-451.
50. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29(10):1239-1246.
51. von Moos R, Seifert B, Simcock M, et al. First-line temozolomide combined with bevacizumab in metastatic melanoma: A multicentre phase II trial (SAKK 50/07). Ann Oncol. 2012;23(2):531-536.
52. Bhatia P, Friedlander P, Zakaria EA, Kandil E. Impact of BRAF mutation status in the prognosis of cutaneous melanoma: An area of ongoing research. Ann Transl Med. 2015;3(2):24.
53. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-Term survival update. Cancer J Sci Am. 2000;6(suppl 1): S11-S14.
54. Agarwala SS. Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther. 2009;9(5):587-595.
55. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. [Erratum appears in J Clin Oncol 2000 Jun;18(11):2351].
56. J Clin Oncol. 2000;18(1):158-166.
57. National Cancer Institute. Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma. NLM Identifier: NCT02224781. https://clinicaltrials.gov/ct2/show/NCT02224781 Accessed September 21, 2016.